Full text
EXHIBIT F
Case 1:21-md-02989-CMA Document 577-2 Entered on FLSD Docket 06/16/2023 Page 1 of 6
Exhibit C
Case 2:20-cv-04660-KSM Document 7-5 Filed 11/23/20 Page 1 of 5
Case 1:21-md-02989-CMA Document 577-2 Entered on FLSD Docket 06/16/2023 Page 2 of 6
Pomerantz Law Firm Announces the
Filing of a Class Action against Teva
Pharmaceuticals Industries Limited
and Certain Officers - TEVA
NEWS PROVIDED BY
Pomerantz LLP
Sep 23, 2020, 20:20 ET
○
NEW YORK, Sept. 23, 2020 /PRNewswire/ -- Pomerantz LLP announces that a
class action lawsuit has been filed against Teva Pharmaceuticals Industries
Limited ("Teva" or the "Company") (NYSE: TEVA) and certain of its officers. The
class action, filed in United States District Court for the Eastern District of
Pennsylvania, and docketed under 20-cv-04660, is on behalf of a class consisting
of all persons other than Defendants who purchased or otherwise, acquired Teva
securities between October 29, 2015 and August 18, 2020, both dates inclusive
(the "Class Period"), seeking to recover damages caused by Defendants' violations
of the federal securities laws and to pursue remedies under Sections 10(b) and 20
(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5
promulgated thereunder, against the Company and certain of its top officials.
If you are a shareholder who purchased Teva securities during the class period,
you have until November 23, 2020, to ask the Court to appoint you as Lead
Plaintiff for the class. A copy of the Complaint can be obtained at www.pomer-
Page 1 of 4
Pomerantz Law Firm Announces the Filing of a Class Action against Teva Pharmaceutica...
11/23/2020
https://www.prnewswire.com/news-releases/pomerantz-law-firm-announces-the-filing-of...
Case 2:20-cv-04660-KSM Document 7-5 Filed 11/23/20 Page 2 of 5
Case 1:21-md-02989-CMA Document 577-2 Entered on FLSD Docket 06/16/2023 Page 3 of 6
antzlaw.com. To discuss this action, contact Robert S. Willoughby at
newaction@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
7980. Those who inquire by e-mail are encouraged to include their mailing
address, telephone number, and the number of shares purchased.
[Click here for information about joining the class action]
Teva, a pharmaceutical company, develops, manufactures, markets, and
distributes generic medicines, specialty medicines, and biopharmaceutical
products in North America, Europe, and internationally.
Among Teva's products is Copaxone (glatiramer acetate), a prescription drug that
is used to treat relapsing forms of multiple sclerosis ("MS"). Throughout the Class
Period, Teva consistently described Copaxone as the Company's "leading
specialty medicine," reporting Copaxone sales and revenues that consistently
dwarfed the same metrics for other Teva specialty products. Teva attributed
Copaxone's commercial success to "having the right mix" of, among other things,
"a fantastic underlying demand," "patients hav[ing] access to it," and an
"unparalleled . . . track record of both efficacy and safety."
The complaint alleges that throughout the Class Period, Defendants made
materially false and misleading statements regarding the Company's business,
operational, and compliance policies. Specifically, Defendants made false and/or
misleading statements and/or failed to disclose that: (i) Teva had made
substantial illegal kickback payments to charitable foundations to cover
Medicare co-payment obligations of patients taking Copaxone; (ii) accordingly,
Teva's revenues derived from Copaxone were in part the product of unlawful
conduct and thus unsustainable; (iii) the foregoing misconduct subjected Teva to
a foreseeable risk of heightened regulatory scrutiny and enforcement, as well as
Page 2 of 4
Pomerantz Law Firm Announces the Filing of a Class Action against Teva Pharmaceutica...
11/23/2020
https://www.prnewswire.com/news-releases/pomerantz-law-firm-announces-the-filing-of...
Case 2:20-cv-04660-KSM Document 7-5 Filed 11/23/20 Page 3 of 5
Case 1:21-md-02989-CMA Document 577-2 Entered on FLSD Docket 06/16/2023 Page 4 of 6
reputational harm when the truth became known; and (iv) as a result, the
Company's public statements were materially false and misleading at all relevant
times.
On August 18, 2020, the United States Department of Justice ("DOJ") issued a
press release announcing that it had filed a complaint against Teva under the
False Claims Act. Specifically, "[t]he government alleges that, from 2007 through
2015, Teva paid The Assistance Fund (TAF) and Chronic Disease Fund (CDF) with
the intent and understanding that the foundations would use Teva's money to
cover the Medicare co-pays of patients taking Copaxone. During the same
period, Teva raised the price of Copaxone from approximately $17,000 per year to
over $73,000 per year."
On this news, Teva's American depositary receipt ("ADR") price fell $1.11 per ADR
from its previous close on August 17, 2020, or 9.6%, to close at $10.48 per ADR on
August 18, 2020, on unusually heavy trading volume.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is
acknowledged as one of the premier firms in the areas of corporate, securities,
and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known
as the dean of the class action bar, the Pomerantz Firm pioneered the field of
securities class actions. Today, more than 80 years later, the Pomerantz Firm
continues in the tradition he established, fighting for the rights of the victims of
securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm
has recovered numerous multimillion-dollar damages awards on behalf of class
members. See www.pomerantzlaw.com.
Page 3 of 4
Pomerantz Law Firm Announces the Filing of a Class Action against Teva Pharmaceutica...
11/23/2020
https://www.prnewswire.com/news-releases/pomerantz-law-firm-announces-the-filing-of...
Case 2:20-cv-04660-KSM Document 7-5 Filed 11/23/20 Page 4 of 5
Case 1:21-md-02989-CMA Document 577-2 Entered on FLSD Docket 06/16/2023 Page 5 of 6
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980
SOURCE Pomerantz LLP
Related Links
www.pomerantzlaw.com
Page 4 of 4
Pomerantz Law Firm Announces the Filing of a Class Action against Teva Pharmaceutica...
11/23/2020
https://www.prnewswire.com/news-releases/pomerantz-law-firm-announces-the-filing-of...
Case 2:20-cv-04660-KSM Document 7-5 Filed 11/23/20 Page 5 of 5
Case 1:21-md-02989-CMA Document 577-2 Entered on FLSD Docket 06/16/2023 Page 6 of 6